Theravance Biopharma Inc (TBPH)

Sector:
HEALTH CARE
Industry:
PHARMACEUTICALS
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Rick E. Winningham
Employees:
110
UGLAND HOUSE, SOUTH CHURCH STREET, GEORGE TOWN, GRAND CAYMAN, CAYMAN ISLANDS KY1-1104
650-808-6000

Theravance Biopharma, Inc. discovers, develops, and commercializes respiratory medicines in the United States, Europe, and Asia. The company offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist used for the treatment of chronic obstructive pulmonary disease (COPD) Its product portfolio also include Izencitinib, a gut-selective pan-janus kinase (JAK) inhibitor.

Data derived from most recent annual or quarterly report
Market Cap 655.017 Million Shares Outstanding75.9 Million Avg 30-day Volume 570.498 Thousand
P/E Ratio0.6755 Dividend Yield0.0 EPS-0.28
Price to Revenue11.4434 Debt to Equity0.0 EBITDA-53.269 Million
Price to Book Value2.094 Operating Margin-141.747 Enterprise Value419.208 Million
Current Ratio7.822 EPS Growth10.117 Quick Ratio6.822
1 Yr BETA 0.5462 52-week High/Low 12.03 / 8.25 Profit Margin1694.1755
Operating Cash Flow Growth-31.9943 Free Cash Flow to Firm (FCFF) TTM -561.926 Million Free Cash Flow to Equity (FCFE) TTM-51.354 Million
Altman Z-Score-0.5643
Earnings Report2023-11-07
View SEC Filings from TBPH instead.

View recent insider trading info

Theravance Biopharma Inc YCharts
Yahoo! Finance finviz
SEC Web Site SEC DEF 14A Filings

Funds Holding TBPH (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
Click for Additional Filters
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding TBPH

Download CSV

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Financial Reporting

Ownership

  • 4: filed on 2023-09-18 by GRAHAM RICHARD A
  • 4: filed on 2023-08-24 by FARNUM RHONDA
  • 4: filed on 2023-08-22 by SAWAF AZIZ
  • 4: filed on 2023-08-22 by GRIMAUD BRETT A.
  • 4: filed on 2023-08-22 by GRAHAM RICHARD A
  • 4: filed on 2023-08-22 by FARNUM RHONDA
  • 4: filed on 2023-08-15 by GRAHAM RICHARD A
  • 4: filed on 2023-07-18 by GRAHAM RICHARD A
  • 4: filed on 2023-06-16 by GRAHAM RICHARD A
  • 4: filed on 2023-06-12 by FARNUM RHONDA

    • Events (8k)

  • 8-K: filed on 2023-09-12:
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-08-07:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-06-09:
    Item 1.02: Termination of a Material Definitive Agreement
  • 8-K: filed on 2023-05-08:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-05-03:
    Item 3.03: Material Modifications to Rights of Security Holders
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
    Item 5.07: Submission of Matters to a Vote of Security Holders
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-04-17:
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-04-11:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 8.01: Other Events
  • 8-K: filed on 2023-03-13:
    Item 7.01: Regulation FD Disclosure
  • 8-K/A: filed on 2023-03-01:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
  • 8-K: filed on 2023-02-28:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits

    • Proposed Sales (Form 144)

  • 144: filed on 2023-05-15:
  • 144: filed on 2023-04-14:
  • 144: filed on 2023-06-08:
  • 144: filed on 2023-06-14:
  • 144: filed on 2023-07-14:
  • 144: filed on 2023-08-11:
  • 144: filed on 2023-09-14:

    • Proxy

    Prospectus

    All

    Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    6.6 Thousand total shares from 3 transactions

    Exercise Derivative Conversion (M)

    none

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    GRAHAM RICHARD A SVP, RESEARCH & DEVELOPMENT

    • Officer
    		 336,803 2023-09-14 15

    FARNUM RHONDA SVP, COMM & MEDICAL AFFAIRS

    • Officer
    		 340,566 2023-08-22 8

    WINNINGHAM RICK E CHIEF EXECUTIVE OFFICER

    • Officer
    • Director
    		 1,704,336 2023-08-20 6

    SAWAF AZIZ SVP & CHIEF FINANCIAL OFFICER

    • Officer
    		 261,859 2023-08-20 5

    GRIMAUD BRETT A. SVP, GEN COUNSEL AND SECRETARY

    • Officer
    		 285,297 2023-08-20 5

    MALKIEL BURTON G

    • Director
    		 115,589 2023-05-02 1

    MITCHELL DEAN J

    • Director
    		 70,018 2023-05-02 1

    BROSHY ERAN

    • Director
    		 70,018 2023-05-02 1

    PAKIANATHAN DEEPIKA

    • Director
    		 36,879 2023-05-02 1

    SMALDONE ALSUP LAURIE

    • Director
    		 53,794 2023-05-02 1

    O'CONNOR DONAL

    • Director
    		 53,018 2023-05-02 2

    GRAY SUSANNAH

    • Director
    		 20,951 2023-05-02 3

    KELLY JAMES CONNOR

    • Director
    		 0 2023-04-11 1

    HINDMAN ANDREW A. SVP, CHIEF FINANCIAL OFFICER

    • Officer
    		 384,714 2022-11-18 1

    SAMAHA ELI

    • 10% Owner
    		 7,012,226 2022-09-20 0

    WEISS ASSET MANAGEMENT LP

    WEISS ANDREW M

    WAM GP LLC

    • 10% Owner
    		 7,457,060 2022-09-19 0

    GSK PLC

    • FORMER 10% OWNER
    		 0 2022-09-16 0

    YOUNG WILLIAM D

    • Director
    		 106,010 2022-04-26 0

    PITZER KENNETH R SVP, PROD STRAT & COMM PLNG

    • Officer
    		 380,123 2022-02-18 0

    BRADY ANN PRESIDENT, TBIL

    • Officer
    		 110,319 2022-02-18 0

    PASQUALONE FRANK SVP, CHIEF BUSINESS OFFICER

    • Officer
    		 429,783 2021-11-19 0

    WORBOYS PHILIP D SVP, RESEARCH & TRANSL SCIENCE

    • Officer
    		 330,752 2021-11-19 0

    SABESAN VIJAY SVP, TECHNICAL OPERATIONS

    • Officer
    		 235,524 2021-11-19 0

    SHAFER BRADFORD J EVP, GEN. COUNSEL, SECRETARY

    • Officer
    		 277,831 2021-08-20 0

    WHITESIDES GEORGE M

    • Director
    		 249,076 2021-04-27 0

    GUNDERSON ROBERT V JR

    • Director
    		 78,940 2021-04-27 0

    MOLINEAUX SUSAN

    • Director
    		 51,034 2021-04-27 0

    HAUMANN BRETT K CHIEF MEDICAL OFFICER

    • Officer
    		 242,499 2021-02-20 0

    HEGDE SHARATHCHANDRA S SVP, RESEARCH

    • Officer
    		 259,900 2019-08-20 0

    RINGROSE PETER S

    • Director
    		 37,999 2019-04-30 0

    SULIMAN SHEHNAAZ SVP, CORP DEV & STRATEGY

    • Officer
    		 97,198 2019-02-20 0

    GALA RENEE D SVP, CHIEF FINANCIAL OFFICER

    • Officer
    		 157,657 2018-11-20 0

    FORE HENRIETTA

    • Director
    		 24,000 2017-08-11 0

    LEE JUNNING SR. VP, TECHNICAL OPERATIONS

    • Officer
    		 234,071 2017-02-20 0

    MAMMEN MATHAI SVP, RESEARCH & DEVELOPMENT

    • Officer
    		 288,111 2016-03-15 0

    BLUM LEONARD M SR VP, CHIEF COMM. OFFICER

    • Officer
    		 182,731 2016-02-20 0

    ATIEH MICHAEL G

    • Director
    		 0 2014-06-03 0

    JONKER JEFFREY DAVID SENIOR VP, CORP. & BUS. DEV.

    • Officer
    		 0 2014-06-03 0

    THERAVANCE INC

    • 10% Owner
    		 0 2014-05-15 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed    		 Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

    GRAHAM RICHARD A - Officer SVP, RESEARCH & DEVELOPMENT

    		2023-09-18 18:08:53 -0400 2023-09-14 S 2,482 $9.89 d 336,803 direct yes 0.7786 -1.0011 4.2269 5 -1.0011 6

    FARNUM RHONDA - Officer SVP, COMM & MEDICAL AFFAIRS

    		2023-08-24 18:05:07 -0400 2023-08-22 S 1,807 $9.47 d 340,566 direct yes 1.6931 3.8095 3.8095 6 0.0 1

    FARNUM RHONDA - Officer SVP, COMM & MEDICAL AFFAIRS

    		2023-08-22 18:10:22 -0400 2023-08-20 F 10,460 $9.70 d 342,373 direct -1.2526 2.0877 2.0877 6 -1.357 3

    GRAHAM RICHARD A - Officer SVP, RESEARCH & DEVELOPMENT

    		2023-08-22 18:13:01 -0400 2023-08-20 F 10,461 $9.70 d 339,285 direct -1.2526 2.0877 2.0877 6 -1.357 3

    GRIMAUD BRETT A. - Officer SVP, GEN COUNSEL AND SECRETARY

    		2023-08-22 18:15:02 -0400 2023-08-20 F 8,912 $9.70 d 285,297 direct -1.2526 2.0877 2.0877 6 -1.357 3

    SAWAF AZIZ - Officer SVP & CHIEF FINANCIAL OFFICER

    		2023-08-22 18:17:08 -0400 2023-08-20 F 7,114 $9.70 d 261,859 direct -1.2526 2.0877 2.0877 6 -1.357 3

    WINNINGHAM RICK E - Director - Officer CHIEF EXECUTIVE OFFICER

    		2023-08-22 18:19:19 -0400 2023-08-20 F 15,804 $9.70 d 1,611,769 direct -1.2526 2.0877 2.0877 6 -1.357 3

    GRAHAM RICHARD A - Officer SVP, RESEARCH & DEVELOPMENT

    		2023-08-15 18:09:43 -0400 2023-08-11 S 2,322 $9.99 d 349,746 direct yes -1.2308 -1.7436 -14.0513 3.3846 18 -14.0513 31

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available
    THERAVANCE BIOPHARMA INC TBPH 2023-09-29 22:15:03 UTC 4.6855 0.6345 300000
    THERAVANCE BIOPHARMA INC TBPH 2023-09-29 21:45:04 UTC 4.6855 0.6345 300000
    THERAVANCE BIOPHARMA INC TBPH 2023-09-29 21:15:03 UTC 4.6855 0.6345 300000
    THERAVANCE BIOPHARMA INC TBPH 2023-09-29 20:45:05 UTC 4.6855 0.6345 300000
    THERAVANCE BIOPHARMA INC TBPH 2023-09-29 20:15:04 UTC 4.6855 0.6345 300000
    THERAVANCE BIOPHARMA INC TBPH 2023-09-29 19:45:04 UTC 4.6855 0.6345 300000
    THERAVANCE BIOPHARMA INC TBPH 2023-09-29 19:15:03 UTC 0.0 0.0 300000
    THERAVANCE BIOPHARMA INC TBPH 2023-09-29 18:45:03 UTC 0.0 0.0 300000
    THERAVANCE BIOPHARMA INC TBPH 2023-09-29 18:15:03 UTC 0.0 0.0 300000
    THERAVANCE BIOPHARMA INC TBPH 2023-09-29 17:45:03 UTC 4.6914 0.6286 300000
    THERAVANCE BIOPHARMA INC TBPH 2023-09-29 17:15:04 UTC 4.6914 0.6286 300000
    THERAVANCE BIOPHARMA INC TBPH 2023-09-29 16:45:04 UTC 4.6914 0.6286 300000
    THERAVANCE BIOPHARMA INC TBPH 2023-09-29 16:15:03 UTC 4.6914 0.6286 300000
    THERAVANCE BIOPHARMA INC TBPH 2023-09-29 15:45:04 UTC 4.6914 0.6286 300000
    THERAVANCE BIOPHARMA INC TBPH 2023-09-29 15:15:04 UTC 4.6914 0.6286 300000
    THERAVANCE BIOPHARMA INC TBPH 2023-09-29 14:45:04 UTC 4.6914 0.6286 300000
    THERAVANCE BIOPHARMA INC TBPH 2023-09-29 14:15:04 UTC 4.6914 0.6286 300000
    THERAVANCE BIOPHARMA INC TBPH 2023-09-29 13:45:03 UTC 4.7664 0.5536 300000
    THERAVANCE BIOPHARMA INC TBPH 2023-09-29 13:15:04 UTC 4.7664 0.5536 300000
    THERAVANCE BIOPHARMA INC TBPH 2023-09-29 12:45:05 UTC 4.7664 0.5536 300000

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin
    FundVantage Trust- Gotham Defensive Long Fund TBPH -82.0 shares, $-1895.02 2020-03-31 N-PORT
    Prudential Investment Portfolios 12- PGIM QMA Large-Cap Core Equity Plus Fund TBPH -1900.0 shares, $-27588.0 2021-06-30 N-PORT
    Prudential Investment Portfolios 12- PGIM QMA Long-Short Equity Fund TBPH -4400.0 shares, $-32560.0 2021-09-30 N-PORT
    Advanced Series Trust- AST QMA U.S. Equity Alpha Portfolio TBPH -36200.0 shares, $-267880.0 2021-09-30 N-PORT

    No recent transactions

    *** To see all congressional transactions (since 2022) for this stock, please use the congressional transaction search page***

    WhaleWisdom Logo

    Elevate your investments